The Food and Drug Administration's approval of a pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex.
Placed in historical perspective, the popular opposition to things like GMOs and vaccines, much like 19th-century opposition to fertilizers and insecticides, reflects less an overt rejection of science than a distrust of experts who peddle it.
A bill that would speed up approval for medications and medical devices shows how a major initiative can get traction even in the midst of Washington gridlock—but critics say all the lobbying is drowning out some warnings about patient safety.
Internal company documents that have emerged in a New Jersey trial make clear that marketing for Tylenol did not convey doctors’ concerns about its risks.